Hims & Hers Insiders Sell Shares as Company Expands into Testosterone Therapy and Posts Strong Revenue Growth

Recent SEC filings show Hims & Hers executives—COO Michael Chi, Chief Legal Officer Soleil Boughton, and Chief Medical Officer Patrick Harrison Carroll—selling shares worth between $0.3 million and $1.3 million on August 14. All sales were non‑discretionary tax withholding transactions and do not signal a shift in confidence. The company is accelerating its push into testosterone replacement therapy, targeting a near $100 million annual run rate, while reporting 38% quarterly revenue growth to $753.2 million and raising full‑year guidance to $3.1‑$3.3 billion.

HIMS disclosed multiple insider transactions on August 14, with Chief Operating Officer Michael Chi selling 47,702 shares for about $1.3 million, Chief Legal Officer Soleil Boughton offloading 21,500 shares worth roughly $605,000, and Chief Medical Officer Patrick Harrison Carroll disposing of 10,201 shares valued at $287,158. Each filing notes the sales were routine, non‑discretionary tax withholding events tied to RSU vesting, rather than discretionary investment decisions .

Despite these share disposals, the executives retained substantial equity stakes—Chi still holds 470,687 shares and nearly 600,000 RSUs through 2029, Boughton retains 339,075 shares, and Carroll maintains a sizable position—suggesting continued confidence in the firm's prospects. The filings also highlight the company's aggressive growth agenda, including the recent acquisition of Eucalyptus and a strategic push into new specialties such as testosterone replacement therapy, which is approaching a $100 million annual run rate but may pressure gross margins.

Financially, Hims & Hers reported a 38% year‑over‑year revenue increase to $753.2 million in the latest quarter and upgraded its full‑year revenue guidance to $3.1‑$3.3 billion. However, the firm faces uncertainty from an FTC lawsuit over data‑sharing and billing practices, with a $47.5 million legal contingency already impacting earnings. These mixed signals underscore the importance of monitoring both the company's expansion initiatives and regulatory challenges.

Investors should watch for subsequent insider activity, updates on the testosterone therapy rollout, and any further developments in the FTC case, as these factors will influence market perception of Hims & Hers' growth trajectory and valuation.

Related Stocks

HIMS